Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.725 USD | +0.53% | -0.14% | -7.52% |
Financials (USD)
Sales 2024 * | 1.06M | Sales 2025 * | 170K | Capitalization | 127M |
---|---|---|---|---|---|
Net income 2024 * | -30M | Net income 2025 * | -61M | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | 114M | Net cash position 2025 * | 60.6M | EV / Sales 2025 * | 392 x |
P/E ratio 2024 * |
-2.94
x | P/E ratio 2025 * |
-2.4
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on Vistagen Therapeutics, Inc.
1 day | -0.42% | ||
Current month | -10.98% | ||
1 month | +9.81% | ||
3 months | -2.49% | ||
6 months | +53.09% | ||
Current year | -8.56% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 23-08-20 |
Joshua Prince
COO | Chief Operating Officer | 54 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
CHM | Chairman | 88 | 00-05-31 |
Jerry Gin
BRD | Director/Board Member | 81 | 16-02-29 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 18 M€ | +3.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 4.753 | +1.13% | 88 983 |
24-04-25 | 4.7 | -0.42% | 194,805 |
24-04-24 | 4.72 | -2.28% | 147,555 |
24-04-23 | 4.83 | +1.05% | 189,955 |
24-04-22 | 4.78 | +0.42% | 138,367 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.56% | 127M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.82% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- VTGN Stock